Astellas Pharma Inc. (YPH.F)
Frankfurt · EUR · Healthcare · Drug Manufacturers - General
€14.10 (-1.40%) as of
Key statistics
- Market cap
- 25.28B
- P/E (TTM)
- 11.28
- EPS (TTM)
- 1.25
- Dividend yield
- 3.53%
- 52-week range
- 8.69 – 14.30
- Beta
- 0.09
- Revenue (TTM)
- 2.27T
- Profit margin
- 16.05%
- Volume
- 866.00
About Astellas Pharma Inc.
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Chuo, Japan
- Employees
- 14,099
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.